- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06807437
Lanreotid versus placebo před chirurgickým zákrokem, aby se zabránilo chirurgické komplikaci zvané pankreatická fistula
Randomizovaná fáze III slepá studie lanreotidu pro prevenci pooperační píštěné píštěle
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
Přehled studie
Postavení
Podmínky
Detailní popis
PRIMARY OBJECTIVE:
I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.
SECONDARY OBJECTIVES:
I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.
II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.
ADDITIONAL OBJECTIVES:
I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.
II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.
BANKING OBJECTIVE:
I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Dana Sparks
- Telefonní číslo: 210-614-8808
- E-mail: dsparks@swog.org
Studijní záloha kontaktů
- Jméno: Andrea Garcia
- Telefonní číslo: 210-614-8808
- E-mail: agarcia@swog.org
Studijní místa
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- Pozastaveno
- University of Alabama at Birmingham Cancer Center
-
Daphne, Alabama, Spojené státy, 36526
- Pozastaveno
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, Spojené státy, 36532
- Pozastaveno
- Thomas Hospital
-
Mobile, Alabama, Spojené státy, 36607
- Pozastaveno
- Mobile Infirmary Medical Center
-
Saraland, Alabama, Spojené státy, 36571
- Pozastaveno
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Gilbert, Arizona, Spojené státy, 85234
- Pozastaveno
- Banner MD Anderson Cancer Center
-
-
California
-
Duarte, California, Spojené státy, 91010
- Pozastaveno
- City of Hope Comprehensive Cancer Center
-
La Jolla, California, Spojené státy, 92093
- Nábor
- UC San Diego Moores Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 858-822-5354
- E-mail: cancercto@ucsd.edu
-
Vrchní vyšetřovatel:
- Andrew M. Lowy
-
Loma Linda, California, Spojené státy, 92357
- Pozastaveno
- Veterans Affairs Loma Linda Healthcare System
-
Los Angeles, California, Spojené státy, 90033
- Pozastaveno
- USC / Norris Comprehensive Cancer Center
-
San Diego, California, Spojené státy, 92103
- Pozastaveno
- UC San Diego Medical Center - Hillcrest
-
-
Delaware
-
Newark, Delaware, Spojené státy, 19718
- Pozastaveno
- Christiana Care Health System-Christiana Hospital
-
Newark, Delaware, Spojené státy, 19713
- Pozastaveno
- Helen F Graham Cancer Center
-
Newark, Delaware, Spojené státy, 19713
- Pozastaveno
- Medical Oncology Hematology Consultants PA
-
Wilmington, Delaware, Spojené státy, 19801
- Pozastaveno
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Ruskin, Florida, Spojené státy, 33570
- Pozastaveno
- Moffitt Cancer Center at SouthShore
-
Tampa, Florida, Spojené státy, 33612
- Nábor
- Moffitt Cancer Center - McKinley Campus
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
Vrchní vyšetřovatel:
- Andrew J. Sinnamon
-
Tampa, Florida, Spojené státy, 33607
- Pozastaveno
- Moffitt Cancer Center-International Plaza
-
Tampa, Florida, Spojené státy, 33612
- Pozastaveno
- Moffitt Cancer Center
-
Wesley Chapel, Florida, Spojené státy, 33544
- Pozastaveno
- Moffitt Cancer Center at Wesley Chapel
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30342
- Pozastaveno
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Spojené státy, 30308
- Pozastaveno
- Emory University Hospital Midtown
-
Atlanta, Georgia, Spojené státy, 30322
- Pozastaveno
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Spojené státy, 30303
- Pozastaveno
- Grady Health System
-
Johns Creek, Georgia, Spojené státy, 30097
- Pozastaveno
- Emory Johns Creek Hospital
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Nábor
- Northwestern University
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 312-695-1301
- E-mail: cancer@northwestern.edu
-
Vrchní vyšetřovatel:
- Akhil Chawla
-
Chicago, Illinois, Spojené státy, 60612
- Nábor
- University of Illinois
-
Vrchní vyšetřovatel:
- Aslam Ejaz
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 312-355-3046
-
Geneva, Illinois, Spojené státy, 60134
- Pozastaveno
- Northwestern Medicine Cancer Center Delnor
-
Oak Brook, Illinois, Spojené státy, 60523
- Pozastaveno
- Northwestern Medicine Oak Brook
-
Orland Park, Illinois, Spojené státy, 60462
- Pozastaveno
- Northwestern Medicine Orland Park
-
Warrenville, Illinois, Spojené státy, 60555
- Pozastaveno
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Pozastaveno
- Indiana University/Melvin and Bren Simon Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40536
- Nábor
- University of Kentucky/Markey Cancer Center
-
Vrchní vyšetřovatel:
- Michael J. Cavnar
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 859-257-3379
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70112
- Pozastaveno
- University Medical Center New Orleans
-
-
Maryland
-
Elkton, Maryland, Spojené státy, 21921
- Pozastaveno
- Christiana Care - Union Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- Pozastaveno
- University of Michigan Rogel Cancer Center
-
Battle Creek, Michigan, Spojené státy, 49017
- Pozastaveno
- Bronson Battle Creek
-
Grand Rapids, Michigan, Spojené státy, 49503
- Pozastaveno
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Spojené státy, 49503
- Pozastaveno
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grand Rapids, Michigan, Spojené státy, 49503
- Pozastaveno
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Muskegon, Michigan, Spojené státy, 49444
- Pozastaveno
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Spojené státy, 49120
- Pozastaveno
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Spojené státy, 49444
- Pozastaveno
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Spojené státy, 49677
- Pozastaveno
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Spojené státy, 49085
- Pozastaveno
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Spojené státy, 49085
- Pozastaveno
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Wyoming, Michigan, Spojené státy, 49519
- Pozastaveno
- University of Michigan Health - West
-
-
Minnesota
-
Aitkin, Minnesota, Spojené státy, 56431
- Pozastaveno
- Riverwood Healthcare Center
-
Baxter, Minnesota, Spojené státy, 56425
- Pozastaveno
- Essentia Health - Baxter Clinic
-
Brainerd, Minnesota, Spojené státy, 56401
- Pozastaveno
- Essentia Health Saint Joseph's Medical Center
-
Crosslake, Minnesota, Spojené státy, 56442
- Pozastaveno
- Essentia Health - Saint Joseph's Crosslake Clinic
-
Deer River, Minnesota, Spojené státy, 56636
- Pozastaveno
- Essentia Health - Deer River Clinic
-
Detroit Lakes, Minnesota, Spojené státy, 56501
- Pozastaveno
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, Spojené státy, 55805
- Pozastaveno
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Spojené státy, 55805
- Pozastaveno
- Miller-Dwan Hospital
-
Duluth, Minnesota, Spojené státy, 55805
- Pozastaveno
- Essentia Health Cancer Center
-
Ely, Minnesota, Spojené státy, 55731
- Pozastaveno
- Essentia Health - Ely Clinic
-
Fosston, Minnesota, Spojené státy, 56542
- Pozastaveno
- Essentia Health - Fosston
-
Hibbing, Minnesota, Spojené státy, 55746
- Pozastaveno
- Essentia Health Hibbing Clinic
-
International Falls, Minnesota, Spojené státy, 56649
- Pozastaveno
- Essentia Health - International Falls Clinic
-
Moose Lake, Minnesota, Spojené státy, 55767
- Pozastaveno
- Essentia Health - Moose Lake Clinic
-
Park Rapids, Minnesota, Spojené státy, 56470
- Pozastaveno
- Essentia Health - Park Rapids
-
Pequot Lakes, Minnesota, Spojené státy, 56472
- Pozastaveno
- Essentia Health - Saint Joseph's Pequot Lakes Clinic
-
Pine River, Minnesota, Spojené státy, 56474
- Pozastaveno
- Essentia Health - Saint Joseph's Pine River Clinic
-
Sandstone, Minnesota, Spojené státy, 55072
- Pozastaveno
- Essentia Health Sandstone
-
Staples, Minnesota, Spojené státy, 56479
- Pozastaveno
- Essentia Health - Saint Joseph's Staples Clinic
-
Virginia, Minnesota, Spojené státy, 55792
- Pozastaveno
- Essentia Health Virginia Clinic
-
-
Missouri
-
Farmington, Missouri, Spojené státy, 63640
- Nábor
- Parkland Health Center - Farmington
-
Vrchní vyšetřovatel:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 314-996-5569
-
Sainte Genevieve, Missouri, Spojené státy, 63670
- Nábor
- Sainte Genevieve County Memorial Hospital
-
Vrchní vyšetřovatel:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 314-996-5569
-
St Louis, Missouri, Spojené státy, 63131
- Nábor
- Missouri Baptist Medical Center
-
Vrchní vyšetřovatel:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 314-996-5569
-
Sullivan, Missouri, Spojené státy, 63080
- Nábor
- Missouri Baptist Sullivan Hospital
-
Vrchní vyšetřovatel:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 314-996-5569
-
Sunset Hills, Missouri, Spojené státy, 63127
- Nábor
- BJC Outpatient Center at Sunset Hills
-
Vrchní vyšetřovatel:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 314-996-5569
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68198
- Pozastaveno
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, Spojené státy, 89502
- Pozastaveno
- Renown Regional Medical Center
-
-
New Jersey
-
Livingston, New Jersey, Spojené státy, 07039
- Pozastaveno
- Saint Barnabas Medical Center
-
New Brunswick, New Jersey, Spojené státy, 08903
- Pozastaveno
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Spojené státy, 87106
- Pozastaveno
- University of New Mexico Cancer Center
-
-
New York
-
Rochester, New York, Spojené státy, 14642
- Pozastaveno
- University of Rochester
-
Syracuse, New York, Spojené státy, 13210
- Pozastaveno
- State University of New York Upstate Medical University
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 28203
- Pozastaveno
- Carolinas Medical Center/Levine Cancer Institute
-
Concord, North Carolina, Spojené státy, 28025
- Pozastaveno
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Fargo, North Dakota, Spojené státy, 58103
- Pozastaveno
- Essentia Health Cancer Center-South University Clinic
-
Fargo, North Dakota, Spojené státy, 58122
- Pozastaveno
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Spojené státy, 58122
- Pozastaveno
- Sanford Broadway Medical Center
-
Jamestown, North Dakota, Spojené státy, 58401
- Pozastaveno
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45219
- Pozastaveno
- University of Cincinnati Cancer Center-UC Medical Center
-
Columbus, Ohio, Spojené státy, 43210
- Pozastaveno
- Ohio State University Comprehensive Cancer Center
-
West Chester, Ohio, Spojené státy, 45069
- Pozastaveno
- University of Cincinnati Cancer Center-West Chester
-
-
Pennsylvania
-
Allentown, Pennsylvania, Spojené státy, 18104
- Nábor
- Saint Luke's Cancer Center - Allentown
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 610-776-4714
-
Vrchní vyšetřovatel:
- Darius C. Desai
-
Bethlehem, Pennsylvania, Spojené státy, 18015
- Nábor
- Saint Luke's University Hospital-Bethlehem Campus
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 484-503-4151
-
Vrchní vyšetřovatel:
- Darius C. Desai
-
Chadds Ford, Pennsylvania, Spojené státy, 19317
- Pozastaveno
- Christiana Care Health System-Concord Health Center
-
Easton, Pennsylvania, Spojené státy, 18045
- Nábor
- Saint Luke's Hospital-Anderson Campus
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Vrchní vyšetřovatel:
- Darius C. Desai
-
Quakertown, Pennsylvania, Spojené státy, 18951
- Nábor
- Saint Luke's Hospital - Upper Bucks Campus
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 610-776-4714
-
Vrchní vyšetřovatel:
- Darius C. Desai
-
Stroudsburg, Pennsylvania, Spojené státy, 18360
- Nábor
- Saint Luke's Hospital - Monroe Campus
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Vrchní vyšetřovatel:
- Darius C. Desai
-
Wilkes-Barre, Pennsylvania, Spojené státy, 18711
- Pozastaveno
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Spojené státy, 57104
- Pozastaveno
- Sanford Cancer Center Oncology Clinic
-
Sioux Falls, South Dakota, Spojené státy, 57117-5134
- Pozastaveno
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Spojené státy, 37920
- Pozastaveno
- University of Tennessee - Knoxville
-
Memphis, Tennessee, Spojené státy, 38120
- Pozastaveno
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Vermont
-
Burlington, Vermont, Spojené státy, 05405
- Pozastaveno
- University of Vermont and State Agricultural College
-
Burlington, Vermont, Spojené státy, 05401
- Pozastaveno
- University of Vermont Medical Center
-
-
Virginia
-
Richmond, Virginia, Spojené státy, 23235
- Nábor
- VCU Massey Cancer Center at Stony Point
-
Kontakt:
- Site Public Contact
- E-mail: ctoclinops@vcu.edu
-
Vrchní vyšetřovatel:
- Leopoldo J. Fernandez
-
Richmond, Virginia, Spojené státy, 23298
- Nábor
- VCU Massey Comprehensive Cancer Center
-
Vrchní vyšetřovatel:
- Leopoldo J. Fernandez
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
Roanoke, Virginia, Spojené státy, 24033
- Pozastaveno
- Carilion Roanoke Memorial Hospital
-
Winchester, Virginia, Spojené státy, 22601
- Pozastaveno
- Valley Health / Winchester Medical Center
-
-
Washington
-
Seattle, Washington, Spojené státy, 98195
- Pozastaveno
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Spojené státy, 98109
- Pozastaveno
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Ashland, Wisconsin, Spojené státy, 54806
- Pozastaveno
- Northwest Wisconsin Cancer Center
-
Ashland, Wisconsin, Spojené státy, 54806
- Pozastaveno
- Duluth Clinic Ashland
-
Hayward, Wisconsin, Spojené státy, 54843
- Pozastaveno
- Essentia Health-Hayward Clinic
-
Hayward, Wisconsin, Spojené státy, 54843
- Pozastaveno
- Tamarack Health Hayward Medical Center
-
Marshfield, Wisconsin, Spojené státy, 54449
- Nábor
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonní číslo: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Vrchní vyšetřovatel:
- Jessica A. Wernberg
-
Mukwonago, Wisconsin, Spojené státy, 53149
- Pozastaveno
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Spojené státy, 53066
- Pozastaveno
- ProHealth Oconomowoc Memorial Hospital
-
Spooner, Wisconsin, Spojené státy, 54801
- Pozastaveno
- Essentia Health-Spooner Clinic
-
Superior, Wisconsin, Spojené státy, 54880
- Pozastaveno
- Essentia Health Saint Mary's Hospital - Superior
-
Waukesha, Wisconsin, Spojené státy, 53188
- Pozastaveno
- ProHealth Waukesha Memorial Hospital
-
Waukesha, Wisconsin, Spojené státy, 53188
- Pozastaveno
- UW Cancer Center at ProHealth Care
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential
-
Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date
-
Participants must not have a known history of a prior diagnosis of malabsorption syndrome
-
Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization
-
Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization
-
Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization
-
Participants must be ≥ 18 years old
-
Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization
-
Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization
-
Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:
- Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
- Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
- Bromocriptine: Dose adjustments may be considered to account for absorption changes
- Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
- CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy
- NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation
-
Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable
-
Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)
-
Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
-
Participants must be offered the opportunity to participate in specimen banking
-
Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study
-
NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
-
For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Arm I (lanreotide, distal pancreatectomy)
Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
Ostatní jména:
Undergo distal pancreatectomy Given SC
Ostatní jména:
|
|
Komparátor placeba: Arm II (saline placebo, distal pancreatectomy)
Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
Ostatní jména:
Undergo distal pancreatectomy Given SC
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of postoperative pancreatic fistula (POPF)
Časové okno: Up to 60 days after distal pancreatectomy
|
POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of biochemical leak (BL)
Časové okno: Up to 60 days after distal pancreatectomy
|
BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Number of post-operation hospital days
Časové okno: From the time of surgery up to 60 days after distal pancreatectomy
|
Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor. |
From the time of surgery up to 60 days after distal pancreatectomy
|
|
Change in overall quality of life (QOL)
Časové okno: At baseline and at 14 and 60 days after surgery
|
Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and at 14 and 60 days after surgery
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Changes in pancreatic specific QOL
Časové okno: At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Change in health-related QOL
Časové okno: At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Delayed gastric emptying (DGE)
Časové okno: Up to 60 days after distal pancreatectomy
|
DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
Časové okno: Up to 60 days after distal pancreatectomy
|
PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Time to initiation of adjuvant chemotherapy
Časové okno: From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test. |
From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
|
Incidence of nausea and vomiting
Časové okno: Up to 60 days after distal pancreatectomy
|
Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test. |
Up to 60 days after distal pancreatectomy
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Jonathan G Sham, SWOG Cancer Research Network
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Onemocnění endokrinního systému
- Novotvary podle místa
- Novotvary
- Novotvary trávicího systému
- Nemoci trávicího systému
- Novotvary endokrinních žláz
- Onemocnění slinivky břišní
- Novotvary pankreatu
- Farmaceutické přípravky
- Vyšetřovací techniky
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Anorganické chemikálie
- Sloučeniny chloru
- Krystaloidní roztoky
- Izotonická řešení
- Řešení
- Sloučeniny sodíku
- Chloridy
- Kyselina chlorovodíková
- Solný roztok
- Manipulace se vzorkem
- Chlorid sodný
- Lanreotid
Další identifikační čísla studie
- S2408
- UG1CA189974 (Grant/smlouva NIH USA)
- NCI-2024-08361 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- SWOG-S2408 (Jiný identifikátor: DCP)
- S2408 (Jiný identifikátor: SWOG)
- S2408 (Jiný identifikátor: CTEP)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .